Beyang Therapeutics

Beyang Therapeutics is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on developing next-generation small molecule drugs for oncology and immunology. The company utilizes a proprietary structure-based drug design (SBDD) and fragment-based drug discovery (FBDD) platform to target historically 'undruggable' proteins. Its lead program, BY-001, is a potent and selective SOS1 inhibitor currently being evaluated in clinical trials for patients with KRAS-mutant solid tumors. Beyang's pipeline also includes several early-stage programs targeting key signaling pathways in cancer cell growth and immune evasion. The company is led by an experienced R&D team with a track record in global pharmaceutical companies. Beyang is supported by prominent venture capital firms and aims to deliver precision therapies to global markets.